

GlaxoSmithKline to launch 2 production lines with EGP 100 mn investments

GlaxoSmithKline plans to inaugurate two new production lines, with investments worth EGP 100 million. The company will open a new line for the manufacture of Voltaren, with investments of EGP 20 million made for this purpose during 2019. The drugmaker will also inaugurate a new line at the El-Salam factory for the production of Otrivin, with EGP 80 million in investments to be made during 2020.